Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

3060 Pegasus Park Drive, Dallas, TX, 75247, United States

Biotechnology
Healthcare

Market Cap

331.2M

52 Wk Range

$4.90 - $35.62

Previous Close

$24.86

Open

$24.46

Volume

241,649

Day Range

$23.47 - $25.76

Enterprise Value

246.8M

Cash

76.96M

Avg Qtr Burn

-16.47M

Insider Ownership

3.16%

Institutional Own.

90.09%

Qtr Updated

12/31/25